Lucy Side
Overview
Explore the profile of Lucy Side including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Falcone M, Pritchard-Jones K, Brok J, Mifsud W, Williams R, Nakata K, et al.
Pediatr Nephrol
. 2021 Oct;
37(4):821-832.
PMID: 34608521
Background: Wilms tumour (WT) survivors, especially patients with associated syndromes or genitourinary anomalies due to constitutional WT1 pathogenic variant, have increased risk of kidney failure. We describe the long-term kidney...
12.
Zou X, Koh G, Nanda A, Degasperi A, Urgo K, Roumeliotis T, et al.
Nat Cancer
. 2021 Jun;
2(6):643-657.
PMID: 34164627
Mutational signatures are imprints of pathophysiological processes arising through tumorigenesis. We generated isogenic CRISPR-Cas9 knockouts (Δ) of 43 genes in human induced pluripotent stem cells, cultured them in the absence...
13.
Nyberg T, Frost D, Barrowdale D, Evans D, Bancroft E, Adlard J, et al.
Eur Urol
. 2020 Jun;
78(4):494-497.
PMID: 32532514
A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 3') wherein pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk than PVs elsewhere in the...
14.
Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32429029
Inclusion Criteria: women ≥18 years. Exclusion Criteria: prior ovarian/tubal/peritoneal cancer, previous genetic testing for OC genes. Participants accessed an online/web-based decision aid along with optional telephone helpline use. Consenting individuals...
15.
Garrett A, Callaway A, Durkie M, Cubuk C, Alikian M, Burghel G, et al.
J Med Genet
. 2020 Mar;
57(12):829-834.
PMID: 32170000
Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly;...
16.
Thorneloe R, Hall L, Walter F, Side L, Lloyd K, Smith S
Cancer Prev Res (Phila)
. 2020 Jan;
13(4):411-422.
PMID: 31988145
Tamoxifen reduces breast cancer incidence in women at increased risk, but may cause side effects. We examined women's knowledge of tamoxifen's potential harms and benefits, and the extent to which...
17.
Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al.
J Clin Oncol
. 2019 Dec;
38(7):674-685.
PMID: 31841383
Purpose: To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline pathogenic variants...
18.
Li H, Terry M, Antoniou A, Phillips K, Kast K, Mooij T, et al.
Cancer Epidemiol Biomarkers Prev
. 2019 Dec;
29(2):368-378.
PMID: 31792088
Background: Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined...
19.
McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, et al.
Int J Gynecol Cancer
. 2019 Nov;
30(2):221-226.
PMID: 31744886
Objective: Pathogenic variants account for 5.8-24.8% of ovarian cancers. The identification of such a variant can have a significant impact on the affected individual and their relatives, determining eligibility for...
20.
Bancroft E, Saya S, Brown E, Thomas S, Taylor N, Rothwell J, et al.
J Med Genet
. 2019 Nov;
57(4):226-236.
PMID: 31719169
Background: Germline gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening...